Pan American League of Associations for Rheumatology treatment recommendations for systemic juvenile idiopathic arthritis
; Fonseca, Adriana Rodrigues ; Barzola, María Lina Cristian ; Cuttica, Rubén J. ; Gutiérrez Suárez, Raúl ; Espada, Graciela ; Silva, Clovis Artur ; Appenzeller, Simone ; Cameto Caffa, Juan A. ; Morel, Zoilo ; Eraso, Ruth ; Ferrandiz, Manuel A. ; Zuccardi, Pilar Guarnizo ; Ibañez Estrella, Amparo ; Rodriguez Tineo, Carmen ; Jiménez Cruz, Karen Viviana ; Jurado, Rosario M. ; León Nogués, Beatriz H. ; Herrera, Cristina N. ; Arroyo Rivera, Ivonne L. ; Faugier Fuentes, Enrique ; Ringer, Ariana ; Ramírez Stieben, Luis Agustín ; Brun, Lucas Ricardo Martín
; Marín Zúcaro, Nicolás M. ; Fernández Ávila, Daniel G. ; Brance, María Lorena
; Talesnik, Eduardo Otros responsables
Fecha
04/2025
Editorial
Oxford University Press
Revista
Rheumatology Advances in Practice
Título del libro
Nombre del evento
Fecha del evento
Institución organizadora
ISSN
2514-1775
eISSN
ISBN
Idioma
Inglés
Tipo del evento
Clasificación temática
Palabras clave
Resumen
Objective: To develop evidence-based Pan American League of Associations for Rheumatology (PANLAR) recommendations for the pharmacologic treatment of Systemic juvenile idiopathic arthritis (sJIA).Methods: An expert panel of Paediatric Rheumatologists from Latin-America (LATAM) generated clinically meaningful research questions structured using the Population, Intervention, Comparator, and Outcome (PICO) format, following Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. A team of methodologists conducted a systematic literature review, extracted and summarised intervention effect estimates, and graded the evidence quality. The JIA expert’s panel voted on each research question structured using the PICO format, which required a minimum agreement of 70% among the voting members and developed recommendations.Results: Four evidence-based recommendations were developed, addressing the two most common phenotypes of sJIA: with predominantly systemic features and with predominantly active synovitis. The optimal therapeutic approach emphasises the early initiation of interleukin-1 or interleukin-6 pathway inhibition, coupled with a non-prolonged course of corticosteroids. For sJIA patients with predominantly systemic features and poor prognostic factors, high-dose intravenous methylprednisolone (“pulse therapy”) is advised. These recommendations highlight the importance of limiting glucocorticoid therapy to the lowest effective dose for the shortest possible duration, with gradual tapering and discontinuation within a maximum period of six months. Conclusion: These recommendations provide guidance on strategies for the use of pharmacological agents for sJIA patients.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by
